Fundraising FoxAtlas Venture — 2024 Investments
11 investments dated 2024 · listed companies and verified rows first · show all
Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.
BiotechFemTechHealthtechConcord, US
Mike Young(Founder)inT Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)inThomas Scott Johnson(Executive Officer, Director)
BoardBrendan Bulik-Sullivan(Director)in
Board seatDavid Grayzel· per SEC Form D
Co-investorsGV (Google Ventures)Broadview VenturesF-Prime CapitalLilly Asia VenturesNew Enterprise Associates (NEA)
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)inScott Biller(Director)in
Board seatKevin Bitterman· per SEC Form D
Co-investorsForesite CapitalThe Column GroupARCH Venture PartnersAlexandriaDecheng Capital
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Judo Bio Co-Founder)inAlfica SehgalinOMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(Executive Chair and Acting CEO)inWilliam Ho
Co-investorsDigitalis VenturesDroia VenturesThe Column GroupYK Bioventures
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical DevicesBoston, US
Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD
Co-investorsNewpath Partners5AM VenturesARCH Venture PartnersDCVC (Data Collective)F-Prime CapitalGV (Google Ventures)+11 more
GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.
BiotechDeep TechHealthtechCambridge, US
Daniel J Mandell(Chief Executive Officer)Tracey Lodie(Executive Officer)inChristopher Gregg(Director)
BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)
Board seatKevin Bitterman· per SEC Form D · $60.4M raise · filed Jul 2024
Co-investorsLeaps by BayerREDMILEAlumni VenturesDigitalis VenturesDreamers VCRising Tide+3 more
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Board seatJean-François Formela· per SEC Form D
Co-investorsAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesNextech InvestVida VenturesAbingworth+3 more
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsDroia VenturesEcoR1 CapitalGV (Google Ventures)The Column GroupAbbVieJJDC+3 more
Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.
AI & Machine LearningBiotechHealthtechWatertown, US
Alex Lugovskoy(Founder and Chief Executive Officer)inMichael Gladstone(Founder)
Co-investorsEcoR1 CapitalFrazier Life SciencesRA CapitalRV Invest GmbHSanofi VenturesViking Global
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Co-investorsAscenta CapitalBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMedViking Global+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ethyreal BioTrace Neuroscience
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.